Meta-Analysis
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 16, 2023; 11(29): 7091-7100
Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.7091
Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma
Pei Wang, Sheng-Yu Jin
Pei Wang, Sheng-Yu Jin, Department of Hematology, Yanbian University Hospital, Yanji 133000, Jilin Province, China
Author contributions: Wang P and Jin SY contributed equally to this work; Wang P designed the study; Jin SY contributed to the analysis of the manuscript; Wang P and Jin SY analyzed the data and contributed to the writing of this article.
Conflict-of-interest statement: All author reports have no conflicts of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sheng-Yu Jin, PhD, Chief Doctor, Doctor, Library Staff, Department of Hematology, Yanbian University Hospital, No. 1327 Juzi Street, Yanji 133000, Jilin Province, China. jinsy11@163.com
Received: August 21, 2023
Peer-review started: August 21, 2023
First decision: September 4, 2023
Revised: September 12, 2023
Accepted: September 22, 2023
Article in press: September 22, 2023
Published online: October 16, 2023
Processing time: 53 Days and 4.9 Hours
Core Tip

Core Tip: Daratumumab demonstrates promising efficacy in treating multiple myeloma, improving the overall response rate, complete remission, and progression-free survival time, compared to other therapies. However, it is also associated with an increased risk of neutropenia and thrombocytopenia. Clinicians should closely monitor their patients for these adverse effects. Further studies are needed to explore optimal dosing and combination therapies to maximize the benefits of daratumumab in treating multiple myeloma.